HIV pre-exposure prophylaxis: Mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model

Virology

Volumn 464-465, Issue 1, 2014, Pages 253-263

  Veselinovic, Milena ^a   Yang, Kuo Hsiung ^b   LeCureux, Jonathan ^a   Sykes, Craig ^b   Remling Mulder, Leila ^a   Kashuba, Angela D M ^b,c   Akkina, Ramesh ^a  

^a Veterinary Dentistry and Oral Surgery   (United States)

^b UNC Hamner Institute for Drug Safety Sciences   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Anti retroviral drug pharmacokinetics in humanized mice; HIV pre exposure prophylaxis in hu mice; Humanized mice for HIV PrEP PK studies; Tenofovir and maraviroc phamacokinetics in hu mice

Indexed keywords

ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CYCLOHEXANE DERIVATIVE; MARAVIROC; PHOSPHONIC ACID DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; TRIAZOLE DERIVATIVE;

ANALOGS AND DERIVATIVES; ANIMAL; DISEASE MODEL; DRUG EFFECTS; FEMALE; HIV INFECTIONS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MOUSE; MUCOSA; PHYSIOLOGY; PRE-EXPOSURE PROPHYLAXIS; VIROLOGY; VIRUS ENTRY;

ADENINE; ANIMALS; ANTI-HIV AGENTS; CYCLOHEXANES; DISEASE MODELS, ANIMAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MICE; MUCOUS MEMBRANE; ORGANOPHOSPHONATES; PRE-EXPOSURE PROPHYLAXIS; REVERSE TRANSCRIPTASE INHIBITORS; TRIAZOLES; VIRUS INTERNALIZATION;

EID: 84905459118     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2014.07.008     Document Type: Article

References (51)

1. Abdool Karim Q., Abdool Karim S.S., Frohlich J.A., Grobler A.C., Baxter C., Mansoor L.E., Kharsany A.B., Sibeko S., Mlisana K.P., Omar Z., Gengiah T.N., Maarschalk S., Arulappan N., Mlotshwa M., Morris L., Taylor D. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010, 329:1168-1174.
2. Abel S., van der Ryst E., Rosario M.C., Ridgway C.E., Medhurst C.G., Taylor-Worth R.J., Muirhead G.J. Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers. Br. J. Clin. Pharmacol. 2008, 65(1):5-18.
3. Adams J.L., Sykes C., Menezes P., Prince H.M., Patterson K.B., Fransen K., Crucitti T., De Baetselier I., Van Damme L., Kashuba A.D. Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence?. J. Acquir. Immune Defic. Syndr. 2013, 62:260-266.
4. Akkina R. New generation humanized mice for virus research: comparative aspects and future prospects. Virology 2013, 435:14-28.
5. Baeten J.M., Donnell D., Ndase P., Mugo N.R., Campbell J.D., Wangisi J., Tappero J.W., Bukusi E.A., Cohen C.R., Katabira E., Ronald A., Tumwesigye E., Were E., Fife K.H., Kiarie J., Farquhar C., John-Stewart G., Kakia A., Odoyo J., Mucunguzi A., Nakku-Joloba E., Twesigye R., Ngure K., Apaka C., Tamooh H., Gabona F., Mujugira A., Panteleeff D., Thomas K.K., Kidoguchi L., Krows M., Revall J., Morrison S., Haugen H., Emmanuel-Ogier M., Ondrejcek L., Coombs R.W., Frenkel L., Hendrix C., Bumpus N.N., Bangsberg D., Haberer J.E., Stevens W.S., Lingappa J.R., Celum C. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N. Engl. J. Med. 2012, 367:399-410.
6. -/- (RAG-hu) mice. Virology 2008, 373:342-351.
7. -/- (RAG-hu) mouse model. Retrovirology 2006, 3:76.
8. Brown K.C., Patterson K.B., Malone S.A., Shaheen N.J., Prince H.M., Dumond J.B., Spacek M.B., Heidt P.E., Cohen M.S., Kashuba A.D. Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men. J. Infect. Dis. 2011, 203:1484-1490.
9. Chateau M.L., Denton P.W., Swanson M.D., McGowan I., Garcia J.V. Rectal transmission of transmitted/founder HIV-1 is efficiently prevented by topical 1% tenofovir in BLT humanized mice. PLoS One 2013, 8:e60024.
10. -/- mouse. J. Virol. 2009, 83:8254-8258.
11. Cohen M.S., Smith M.K., Muessig K.E., Hallett T.B., Powers K.A., Kashuba A.D. Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here?. Lancet 2013, 382:1515-1524.
12. Denton P.W., Estes J.D., Sun Z., Othieno F.A., Wei B.L., Wege A.K., Powell D.A., Payne D., Haase A.T., Garcia J.V. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med. 2008, 5:e16.
13. Denton P.W., Garcia J.V. Humanized mouse models of HIV infection. AIDS Rev. 2011, 13:135-148.
14. Denton P.W., Garcia J.V. Mucosal HIV-1 transmission and prevention strategies in BLT humanized mice. Trends Microbiol. 2012, 20:268-274.
15. Denton P.W., Long J.M., Wietgrefe S.W., Sykes C., Spagnuolo R.A., Snyder O.D., Perkey K., Archin N.M., Choudhary S.K., Yang K., Hudgens M.G., Pastan I., Haase A.T., Kashuba A.D., Berger E.A., Margolis D.M., Garcia J.V. Targeted cytotoxic therapy kills persisting HIV infected cells during ART. PLoS Pathog. 2014, 10:e1003872.
16. Denton P.W., Othieno F., Martinez-Torres F., Zou W., Krisko J.F., Fleming E., Zein S., Powell D.A., Wahl A., Kwak Y.T., Welch B.D., Kay M.S., Payne D.A., Gallay P., Appella E., Estes J.D., Lu M., Garcia J.V. One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates. J. Virol. 2011, 85:7582-7593.
17. Dumond J.B., Patterson K.B., Pecha A.L., Werner R.E., Andrews E., Damle B., Tressler R., Worsley J., Kashuba A.D. Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J. Acquir. Immune Defic. Syndr. 2009, 51:546-553.
18. Dumond J.B., Yeh R.F., Patterson K.B., Corbett A.H., Jung B.H., Rezk N.L., Bridges A.S., Stewart P.W., Cohen M.S., Kashuba A.D. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. Aids 2007, 21:1899-1907.
19. Evans D.T., Silvestri G. Nonhuman primate models in AIDS research. Curr. Opin. HIV AIDS 2013, 8:255-261.
20. Excler J.L., Robb M.L., Kim J.H. HIV-1 vaccines: challenges and new perspectives. Hum. Vaccin Immunother. 2014, 10(6). [Epub ahead of print].
21. Fennessey C.M., Keele B.F. Using nonhuman primates to model HIV transmission. Curr. Opin. HIV AIDS 2013, 8:280-287.
22. Forbes C.J., Lowry D., Geer L., Veazey R.S., Shattock R.J., Klasse P.J., Mitchnick M., Goldman L., Doyle L.A., Muldoon B.C., Woolfson A.D., Moore J.P., Malcolm R.K. Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc. J. Controll. Release 2011, 156:161-169.
23. Garcia-Lerma J.G., Cong M.E., Mitchell J., Youngpairoj A.S., Zheng Q., Masciotra S., Martin A., Kuklenyik Z., Holder A., Lipscomb J., Pau C.P., Barr J.R., Hanson D.L., Otten R., Paxton L., Folks T.M., Heneine W. Intermittent prophylaxis with oral truvada protects macaques from rectal SHIV infection. Sci. Transl. Med. 2010, 2:14ra14.
24. Garcia-Lerma J.G., Otten R.A., Qari S.H., Jackson E., Cong M.E., Masciotra S., Luo W., Kim C., Adams D.R., Monsour M., Lipscomb J., Johnson J.A., Delinsky D., Schinazi R.F., Janssen R., Folks T.M., Heneine W. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med. 2008, 5:e28.
25. Grant R.M., Lama J.R., Anderson P.L., McMahan V., Liu A.Y., Vargas L., Goicochea P., Casapia M., Guanira-Carranza J.V., Ramirez-Cardich M.E., Montoya-Herrera O., Fernandez T., Veloso V.G., Buchbinder S.P., Chariyalertsak S., Schechter M., Bekker L.G., Mayer K.H., Kallas E.G., Amico K.R., Mulligan K., Bushman L.R., Hance R.J., Ganoza C., Defechereux P., Postle B., Wang F., McConnell J.J., Zheng J.H., Lee J., Rooney J.F., Jaffe H.S., Martinez A.I., Burns D.N., Glidden D.V. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 2010, 363:2587-2599.
26. Hawkins T., Veikley W., Claire R.L., Guyer B., Clark N., Kearney B.P. Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. J. Acquir. Immune Defic. Syndr. 2005, 39:406-411.
27. Heneine W., Kashuba A. HIV prevention by oral preexposure prophylaxis. Cold Spring Harb. Perspect. Med. 2012, 2:a007419.
28. Karim S.S., Kashuba A.D., Werner L., Karim Q.A. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet 2011, 378:279-281.
29. Kearney B.P., Flaherty J.F., Shah J. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Clin. Pharmacokinet. 2004, 43:595-612.
30. Kwara A., Delong A., Rezk N., Hogan J., Burtwell H., Chapman S., Moreira C.C., Kurpewski J., Ingersoll J., Caliendo A.M., Kashuba A., Cu-Uvin S. Antiretroviral drug concentrations and HIV RNA in the genital tract of HIV-infected women receiving long-term highly active antiretroviral therapy. Clin. Infect. Dis. 2008, 46:719-725.
31. Malcolm R.K., Forbes C.J., Geer L., Veazey R.S., Goldman L., Klasse P.J., Moore J.P. Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques. J. Antimicrob. Chemother. 2013, 68:678-683.
32. McEnery R. Oral tenofovir arm of VOICE trial discontinued early. IAVI Rep 2011, 15:21.
33. Neff C.P., Kurisu T., Ndolo T., Fox K., Akkina R. A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice. PLoS One 2011, 6:e20209.
34. Neff C.P., Ndolo T., Tandon A., Habu Y., Akkina R. Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model. PLoS One 2010, 5:e15257.
35. Nicol, M.R., Fedoriw, Y., Mathews, M., Prince, H.M., Patterson, K.B., Geller, E., Mollan, K., Mathews, S., Kroetz, D.L., Kashuba, A.D., 2013. Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV prevention. J. Clin. Pharmacol.
36. Nicol M.R., Kashuba A.D. Pharmacologic opportunities for HIV prevention. Clin. Pharmacol. Ther. 2010, 88:598-609.
37. Nischang M., Gers-Huber G., Audige A., Akkina R., Speck R.F. Modeling HIV infection and therapies in humanized mice. Swiss Med. Wkly. 2012, 142:w13618.
38. Nuttall J., Kashuba A., Wang R., White N., Allen P., Roberts J., Romano J. Pharmacokinetics of tenofovir following intravaginal and intrarectal administration of tenofovir gel to rhesus macaques. Antimicrob. Agents Chemother. 2012, 56:103-109.
39. Parikh U.M., Dobard C., Sharma S., Cong M.E., Jia H., Martin A., Pau C.P., Hanson D.L., Guenthner P., Smith J., Kersh E., Garcia-Lerma J.G., Novembre F.J., Otten R., Folks T., Heneine W. Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J. Virol. 2009, 83:10358-10365.
40. Patterson K.B., Prince H.A., Kraft E., Jenkins A.J., Shaheen N.J., Rooney J.F., Cohen M.S., Kashuba A.D. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci. Transl. Med. 112re114 2011, 3.
41. Pennings P.S. HIV drug resistance: problems and perspectives. Infect. Dis. Rep. 2013, 5:e5.
42. Romano J., Kashuba A., Becker S., Cummins J., Turpin J., Veronese F. Pharmacokinetics and pharmacodynamics in HIV prevention; current status and future directions: a summary of the DAIDS and BMGF sponsored think tank on pharmacokinetics (PK)/pharmacodynamics (PD) in HIV prevention. AIDS Res. Hum. Retrovir. 2013, 29:1418-1427.
43. Ruelas D.S., Greene W.C. An integrated overview of HIV-1 latency. Cell 2013, 155:519-529.
44. Thigpen M.C., Kebaabetswe P.M., Paxton L.A., Smith D.K., Rose C.E., Segolodi T.M., Henderson F.L., Pathak S.R., Soud F.A., Chillag K.L., Mutanhaurwa R., Chirwa L.I., Kasonde M., Abebe D., Buliva E., Gvetadze R.J., Johnson S., Sukalac T., Thomas V.T., Hart C., Johnson J.A., Malotte C.K., Hendrix C.W., Brooks J.T. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N. Engl. J. Med. 2012, 367:423-434.
45. Thompson C.G., Cohen M.S., Kashuba A.D. Antiretroviral pharmacology in mucosal tissues. J. Acquir. Immune Defic. Syndr. 2013, 63(Suppl 2):S240-247.
46. To E.E., Hendrix C.W., Bumpus N.N. Dissimilarities in the metabolism of antiretroviral drugs used in HIV pre-exposure prophylaxis in colon and vagina tissues. Biochem. Pharmacol. 2013, 86:979-990.
47. Global report: report on the global AIDS epidemic 2013, UNAIDS, (Joint United Nations Programme on HIV/AIDS (UNAIDS).
48. Van Damme L., Corneli A., Ahmed K., Agot K., Lombaard J., Kapiga S., Malahleha M., Owino F., Manongi R., Onyango J., Temu L., Monedi M.C., Mak'Oketch P., Makanda M., Reblin I., Makatu S.E., Saylor L., Kiernan H., Kirkendale S., Wong C., Grant R., Kashuba A., Nanda K., Mandala J., Fransen K., Deese J., Crucitti T., Mastro T.D., Taylor D. Preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med. 2012, 367:411-422.
49. van der Straten A., Van Damme L., Haberer J.E., Bangsberg D.R. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. Aids 2012, 26:F13-19.
50. Veazey R.S. Animal models for microbicide safety and efficacy testing. Curr. Opin. HIV AIDS 2013, 8:295-303.
51. Vourvahis M., Tappouni H.L., Patterson K.B., Chen Y.C., Rezk N.L., Fiscus S.A., Kearney B.P., Rooney J.F., Hui J., Cohen M.S., Kashuba A.D. The pharmacokinetics and viral activity of tenofovir in the male genital tract. J. Acquir. Immune Defic. Syndr. 2008, 47:329-333.